Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 7/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281581 | 1.00 | GLO1 (0.62) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| Octanedioate SCHEMBL5671265 | 0.96 | GLO1 (0.62) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL13405584 | 0.91 | GLO1 (0.61) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL3280199 | 0.91 | GLO1 (0.60) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL3280191 | 0.91 | GLO1 (0.60) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL3281097 | 0.91 | GLO1 (0.72) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL3279946 | 0.91 | GLO1 (0.60) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL3279951 | 0.91 | GLO1 (0.60) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL3281101 | 0.91 | GLO1 (0.72) | GLO1PTGS1GSTK1FOLH1NOD1 | |
| SCHEMBL5063030 | 0.85 | GLO1 (0.50) | GLO1PTGS1GSTK1NOD1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700560-B2 | Inactivators and bivalent inhibitors of glyoxalase I and methods of inhibiting tumor growth | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2010-04-20 | — | — | US | claimed |
| US-20070287672-A1 | Macromolecular Gsh-Activiated Glyoxylase I Inhibitors | MARYLAND, UNIVERSITY OF, BALTIMORE COUNTY | 2007-12-13 | — | — | US | claimed |
| US-20070129311-A1 | Inactivators and bivalent inhibitors of glyoxalase i and methods inhibiting tumor growth | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2007-06-07 | — | — | US | claimed |
| JP-2006526632-A | — | — | 2006-11-24 | — | — | JP | claimed |
| EP-1628999-A4 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | UNIV MARYLAND (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1628999-A2 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | University of Maryland, Baltimore County (US) | 2006-03-01 | — | — | EP | claimed |
| WO-2005115338-A2 | MACROMOLECULAR GSH-ACTIVATED GLYOXYLASE I INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2005-12-08 | — | — | WO | claimed |
| WO-2005007079-A2 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2005-01-27 | — | — | WO | claimed |
| US-12521426-B2 | Methods and compositions for inhibiting glyoxalase 1 (GLO1) | PALMER ABRAHAM (US) | 2026-01-13 | — | — | US | disclosed |
| US-20220305073-A1 | METHODS AND COMPOSITIONS FOR INHIBITING GLYOXALASE 1 (GLO1) | PALMER ABRAHAM (US) | 2022-09-29 | — | — | US | disclosed |
| US-11235020-B2 | Methods and compositions for inhibiting glyoxalase 1 (GLO1) | DISTLER, Margaret | 2022-02-01 | — | — | US | disclosed |
| US-20160038559-A1 | METHODS AND COMPOSITIONS FOR INHIBITING GLYOXALASE 1 (GLO1) | PALMER, Abraham | 2016-02-11 | — | — | US | disclosed |
| US-7700560-B2 | Inactivators and bivalent inhibitors of glyoxalase I and methods of inhibiting tumor growth | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20070287672-A1 | Macromolecular Gsh-Activiated Glyoxylase I Inhibitors | MARYLAND, UNIVERSITY OF, BALTIMORE COUNTY | 2007-12-13 | — | — | US | disclosed |
| EP-1628999-A4 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | UNIV MARYLAND (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1628999-A2 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | University of Maryland, Baltimore County (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005115338-A2 | MACROMOLECULAR GSH-ACTIVATED GLYOXYLASE I INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005007079-A2 | INACTIVATORS AND BIVALENT INHIBITORS OF GLYOXALASE I AND METHODS OF INHIBITING TUMOR GROWTH | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-5616563-A | ANTITUMOR AGENTS | UNIVERSITY OF MARYLAND BALTIMORE CAMPUS (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996000061-A1 | GLUTATHIONE N-HYDROXYCARBAMOYL THIOESTERS AND METHOD OF INHIBITING NEOPLASTIC GROWTH | UNIVERSITY OF MARYLAND BALTIMORE COUNTY (US) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129311-A1 | Inactivators and bivalent inhibitors of glyoxalase i and methods inhibiting tumor growth | GLS, GLO1, GLRX3 | GLO1 2/4885PTGS1 324/4885GSTK1 27/4885 |
| US-20070287672-A1 | Macromolecular Gsh-Activiated Glyoxylase I Inhibitors | GLO1, GGT1, GSTA1 | GLO1 1/4885PTGS1 80/4885GSTK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.